UNICA IRIS Institutional Research Information System

SCARTOZZI, MARIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 256.709
NA - Nord America 28.204
AS - Asia 14.811
SA - Sud America 2.389
AF - Africa 375
OC - Oceania 45
Continente sconosciuto - Info sul continente non disponibili 20
Totale 302.553
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 249.155
US - Stati Uniti d'America 27.705
SG - Singapore 6.046
CN - Cina 4.614
BR - Brasile 1.831
UA - Ucraina 1.748
VN - Vietnam 1.382
SE - Svezia 1.369
DE - Germania 1.130
FI - Finlandia 1.030
FR - Francia 709
GB - Regno Unito 658
HK - Hong Kong 594
IN - India 377
KR - Corea 300
TR - Turchia 299
CA - Canada 273
BD - Bangladesh 201
AR - Argentina 188
NL - Olanda 181
IQ - Iraq 162
MX - Messico 142
JP - Giappone 138
ZA - Sudafrica 123
RU - Federazione Russa 116
AT - Austria 107
PL - Polonia 96
ID - Indonesia 89
CO - Colombia 84
PK - Pakistan 82
ES - Italia 79
EC - Ecuador 78
PH - Filippine 67
VE - Venezuela 63
BE - Belgio 58
MA - Marocco 58
SA - Arabia Saudita 58
UZ - Uzbekistan 54
IE - Irlanda 51
IR - Iran 47
CL - Cile 45
MY - Malesia 39
AE - Emirati Arabi Uniti 38
AU - Australia 38
TN - Tunisia 34
KE - Kenya 32
JO - Giordania 30
PE - Perù 29
EG - Egitto 28
PY - Paraguay 27
LT - Lituania 24
UY - Uruguay 24
IL - Israele 21
TW - Taiwan 20
AL - Albania 19
NP - Nepal 19
AZ - Azerbaigian 18
DZ - Algeria 18
EU - Europa 18
PT - Portogallo 18
CH - Svizzera 17
CZ - Repubblica Ceca 16
HR - Croazia 16
TH - Thailandia 16
BO - Bolivia 15
ET - Etiopia 14
RO - Romania 14
JM - Giamaica 13
KZ - Kazakistan 13
PA - Panama 12
CI - Costa d'Avorio 11
DK - Danimarca 11
DO - Repubblica Dominicana 11
AM - Armenia 10
BG - Bulgaria 10
CR - Costa Rica 10
KG - Kirghizistan 10
GR - Grecia 9
OM - Oman 9
TT - Trinidad e Tobago 9
HN - Honduras 8
IS - Islanda 8
LB - Libano 8
NG - Nigeria 8
NO - Norvegia 8
SK - Slovacchia (Repubblica Slovacca) 8
BH - Bahrain 7
BY - Bielorussia 7
GE - Georgia 7
LK - Sri Lanka 7
TZ - Tanzania 7
AO - Angola 6
JE - Jersey 6
LV - Lettonia 6
MU - Mauritius 6
MK - Macedonia 5
MN - Mongolia 5
NZ - Nuova Zelanda 5
PS - Palestinian Territory 5
RS - Serbia 5
Totale 302.459
Salva come PNG Salva come JPEG
Città #
Cagliari 238.977
Uta 8.475
Singapore 3.154
Fairfield 2.639
Ashburn 2.539
Dallas 2.070
Woodbridge 1.936
San Jose 1.780
Chandler 1.563
Boardman 1.440
Houston 1.372
Seattle 1.046
Wilmington 1.006
Cambridge 903
Jacksonville 892
Ann Arbor 830
Nyköping 830
Beijing 734
Helsinki 679
Los Angeles 645
Hong Kong 535
Hefei 463
Ho Chi Minh City 431
Lauterbourg 422
The Dalles 418
Dearborn 391
Nanjing 324
New York 318
Hanoi 274
Seoul 273
Santa Clara 255
Buffalo 249
Council Bluffs 239
Boston 223
Shanghai 187
Istanbul 178
Guangzhou 169
Dong Ket 166
Milan 158
San Diego 154
São Paulo 152
Chicago 139
Rome 134
Frankfurt am Main 126
Orem 111
Shenyang 111
Munich 107
Tianjin 105
Toronto 104
Nuremberg 96
Redondo Beach 96
Krefeld 95
London 92
Nanchang 90
Amsterdam 89
Tokyo 89
Hebei 85
Montreal 83
Verona 82
Jiaxing 81
Changsha 78
Rio de Janeiro 74
Chennai 72
Warsaw 68
Baghdad 63
Phoenix 60
Atlanta 58
Da Nang 55
Zhengzhou 55
Brooklyn 54
Lappeenranta 54
Pune 54
Vienna 52
Brussels 51
Johannesburg 51
Norwalk 51
Stockholm 51
Washington 51
Bad Bellingen 49
Tashkent 48
Jinan 47
Manchester 47
Mountain View 47
Shenzhen 47
Sassari 46
Belo Horizonte 44
Columbus 44
Haiphong 44
Florence 43
Dublin 42
Wuhan 42
Orange 41
Salt Lake City 41
Redwood City 40
Hangzhou 39
Mexico City 39
San Francisco 39
Ankara 38
Turku 37
Denver 35
Totale 283.395
Salva come PNG Salva come JPEG
Nome #
Thyroid dysfunction and ultrasonography features in patients with metastatic colorectal cancer treated with Regorafenib: preliminary results from a single prospective cohort study. 4.880
Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy 4.180
Timing of the negative effects of trastuzumab on cardiac mechanics after anthracycline chemotherapy 3.584
Aspirin as a neoadjuvant agent during preoperative chemoradiation for rectal cancer 3.377
Clustered protocadherins methylation alterations in cancer 3.321
BRAF-mutant colorectal cancer, a different breed evolving 3.245
The Role of Aspirin as Antitumoral Agent for Heavily Pretreated Patients With Metastatic Colorectal Cancer Receiving Capecitabine Monotherapy 3.177
Systemic therapy for the treatment of endometrial cancer 3.106
Aspirin and cancer risk 3.092
null 3.029
Regorafenib-induced hypothyroidism and cancer-related fatigue: is there a potential link? 2.982
Thyroid dysfunction and ultrasonography features in patients with metastatic colorectal cancer treated with Regorafenib. Results from a single centre prospective cohort study. 2.949
Molecular-biology-driven treatment for metastatic colorectal cancer 2.771
HOXD8 hypermethylation as a fully sensitive and specific biomarker for biliary tract cancer detectable in tissue and bile samples 2.688
Acetylsalicylic acid as a neo-adjuvant agent during preoperative chemoradiation for rectal cancer 2.679
Breast MRI: Clinical Indications, Recommendations, and Future Applications in Breast Cancer Diagnosis 2.678
Thyroid dysfunction in disguise and treatment-related fatigue in the spotlight among metastatic colorectal cancer patients receiving regorafenib: Implications for clinical management. 2.638
CREAM study: Clinical correlation between ipilimumab-Related colitis And intestinal Microbiote in metastatic melanoma patients 2.577
Aggressive differentiated thyroid cancer with multiple metastases and NRAS and TERT promoter mutations: A case report 2.496
Alterazioni tiroidee funzionali e morfologiche in pazienti affetti da carcinoma del colon-retto metastatico in trattamento con Regorafenib. Risultati di uno studio prospettico. 2.454
Colorectal cancer early detection in stool samples tracing CPG islands methylation alterations affecting gene expression 2.366
Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis 2.335
Alterazioni tiroidee funzionali e morfologiche in pazienti affetti da carcinoma del colon-retto metastatico in trattamento con Regorafenib. 2.333
Gold nanoparticles: A new golden Era in oncology? 2.277
Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded? 2.250
HYPOTHYROIDISM AND THYROID AUTOIMMUNITY AS A PROGNOSTIC BIOMARKER OF BETTER RESPONSE IN METASTATIC CANCER LONG SURVIVORS TREATED WITH SUNITINIB 2.243
Health related quality of life in patients with onco-hematological diseases 2.234
Radiological evaluation of response to immunotherapy in brain tumors: Where are we now and where are we going? 2.204
Immunotherapy associated pulmonary toxicity: Biology behind clinical and radiological features 2.172
The abscopal effect in the era of cancer immunotherapy: a spontaneous synergism boosting anti-tumor immunity? 2.156
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab 2.145
Ipotiroidismo e autoimmunità tiroidea in pazienti affetti da carcinoma renale metastatico trattati con sunitinib con un follow-up di 30 mesi. 2.127
Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: The TOREADOR Study 2.126
Microenvironmental M1 tumor-associated macrophage polarization influences cancer-related anemia in advanced ovarian cancer: Key role of interleukin-6 2.044
Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience 2.044
The immune revolution in gastrointestinal tumours: leading the way or just following? 1.978
Hypothyroidism and thyroid autoimmunity in metastatic renal cell carcinoma patients treated with sunitinib: 2 years follow-up of long survivors from a single centre experience. 1.959
From central to sentral (Serum angiogenesis central): Circulating predictive biomarkers to anti-VEGFR therapy 1.911
A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the 'BRAF BeCool' study 1.860
Next generation sequencing driven successful combined treatment with laparoscopic surgery and immunotherapy for relapsed stage IVB cervical and synchronous stage IV lung cancer 1.790
Critical features and challenges associated with imaging in patients undergoing cancer immunotherapy 1.695
The Quality of Life of People with Solid Cancer is Less Worse than Other Diseases with better Prognosis, Except in the Presence of Depression 1.673
New therapeutic targets in pancreatic cancer 1.640
Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials 1.635
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study 1.595
Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients 1.563
Why precision medicine should be applied across the continuum of care for metastatic colorectal cancer patients? 1.546
Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: Training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier) 1.521
Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter 1.463
Tumor infiltrating lymphocytes in gastrointestinal tumors: Controversies and future clinical implications 1.417
ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib 1.410
Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy 1.407
Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations 1.393
Hepatocellular carcinoma and microbiota: Implications for clinical management and treatment 1.361
The distinctive molecular, pathological and clinical characteristics of BRAF-mutant colorectal tumors 1.345
Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study 1.326
Second-line chemotherapy for advanced pancreatic cancer: Which is the best option? 1.299
Immunotherapy for colorectal cancer: where are we heading? 1.277
First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial 1.268
Cancer immunotherapy-associated hypophysitis 1.254
The prognostic role of hemoglobin levels in patients undergoing concurrent chemo-radiation for anal cancer 1.243
Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma 1.231
Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers? 1.225
Molecular-driven treatment for biliary tract cancer: the promising turning point 1.223
The role of fetal programming in human carcinogenesis - May the Barker hypothesis explain interindividual variability in susceptibility to cancer insurgence and progression? 1.220
Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis 1.202
The prognostic impact of primary tumour location in patients with stage II and stage III colon cancer receiving adjuvant therapy. A GISCAD analysis from three large randomised trials 1.200
How to improve metastatic pancreatic ductal adenocarcinoma patients' selection: Between clinical trials and the real-world 1.195
Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced hcc patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group 1.187
eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: Final results of the ePHAS study 1.139
Interplay Between SIRT-3, Metabolism and Its Tumor Suppressor Role in Hepatocellular Carcinoma 1.133
Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma: Myth or Reality? 1.096
CDX-2 expression correlates with clinical outcomes in MSI-H metastatic colorectal cancer patients receiving immune checkpoint inhibitors 1.080
null 1.080
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An Innovate study protocol 1.074
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study 1.050
Colorectal cancer promoter methylation alteration affects the expression of glutamate ionotropic receptor AMPA type subunit 4 alternative isoforms potentially relevant in colon tissue 1.045
Lactate dehydrogenase in hepatocellular carcinoma: something old, something new 1.039
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale 1.030
The association between Major Depressive Disorder and premature death risk in hematologic and solid cancer: a longitudinal cohort study 1.020
Multidisciplinary clinical guidelines in proactive monitoring, early diagnosis, and effective management of trastuzumab deruxtecan (T-DXd)-induced interstitial lung disease (ILD) in breast cancer patients 1.016
Antiangiogenic agents after first line and sorafenib plus chemoembolization: A systematic review 1.015
Neoadjuvant chemo-radiotherapy response in patients affected by mismatch repair deficient (dMMR) locally advanced rectal cancer 991
Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: A retrospective study 978
Systemic chemotherapy for advanced rare pancreatic histotype tumors: A retrospective multicenter analysis 975
Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma 973
Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab 967
Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: Results from the phase III randomised CORRECT trial 963
Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib 962
Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients 962
FOLFOX or CAPOX in stage II to III colon cancer: Efficacy results of the italian three or six colon adjuvant trial 950
Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma 941
Balance between the stem cell marker CD44 and CDX2 expression in colorectal cancer 940
Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast? 939
STUDY OF VALIDATION OF ANGIOGENESIS POLYMORPHISMS IN HCC PATIENTS TREATEDWITH SORAFENIB. INNOVATE STUDY 935
Impact of Aspirin on clinical outcome in advanced HCC patients receiving sorafenib and regorafenib 902
The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer 886
A Multidisciplinary Approach to Patients with Psoriasis and a History of Malignancies or On-Treatment for Solid Tumors: A Narrative Literature Review 885
The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment 874
The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma 866
Totale 175.177
Salva come PNG Salva come JPEG
Categoria #
all - tutte 471.474
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 471.474
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20214.672 0 0 0 0 0 0 0 0 0 0 2.661 2.011
2021/202217.497 1.352 1.105 469 843 911 960 717 3.198 1.945 1.597 2.150 2.250
2022/202328.830 3.008 3.934 3.119 2.545 2.382 2.998 1.411 2.068 2.109 1.809 2.167 1.280
2023/202433.122 1.257 1.347 1.666 2.049 2.733 4.826 4.990 4.292 1.998 1.969 2.911 3.084
2024/202564.461 13.438 14.638 7.457 7.684 3.957 4.662 7.252 599 1.296 1.118 984 1.376
2025/202628.375 1.772 1.207 3.735 2.701 2.022 2.111 6.587 2.098 2.083 3.369 690 0
Totale 304.224